Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India

Indian Journal of Pharmacology

Volumn 44, Issue 4, 2012, Pages 500-503

  Patra, Pradyumna ^a   Guha, Subhasish K ^b   Maji, Ardhendu Kumar ^b   Saha, Pabitra ^b   Ganguly, Swagata ^b   Chakraborty, Abhiram ^b   Kundu, Pratip K ^b   Sarker, Sachchidananda ^c   Ray, Krishnangshu ^b  

^a Canning Sub Divisional Hospital   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^c NONE

Author keywords

India; miltefosine; visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; MILTEFOSINE;

ABDOMINAL PAIN; ADULT; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; RELAPSE; RURAL AREA; VISCERAL LEISHMANIASIS; VOMITING;

INDIA; MILTEFOSINE; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CHILD; FEMALE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; RURAL POPULATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865799445     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.99326     Document Type: Article

References (11)

1. World Health Organization. Leishmaniasis: Burden of disease. Available from: http://www.who.int/leishmaniasis/burden/en. [Last cited in 2009. Aug].
2. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, et al. Amphotericin B treatment for Indian visceral leishmaniasis: Response to15. daily versus alternate-day infusions. Clin Infect Dis 2007;45:556-61.
3. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18.
4. Boelaert M, Criel B, Leeuwenburg J, Van Damme W, Le Ray D, van der Stuyft P. Visceral leishmaniasis control: A public health perspective. Trans R Soc Trop Med Hyg 2000;94:465-71.
5. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501.
6. World Health Organization. Global plan to combat neglected tropical diseases 2008-2015. Available from: http://whqlibdoc.who.int/hq/2007/WHO CDS NTD 2007.3 eng.pdf. [Last cited in 2009. Aug].
7. Regional strategic framework for elimination of VL from SEA Region (2005-2015). New Delhi: WHO-SEARO. SEA-VBC-8. (Rev. 15). p. 22.
8. Communicable diseases: Kala-azar status in SEA region 2005. (online). Available from: http://www.searo.who.int/en/Section10/Section2163.htm.
9. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
10. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with Indian visceral leishmaniasis. Pediatr Infect Dis J 2003;22:434-8.
11. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004;38:217-21.